Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: A retrospective cohort study

被引：47

作者：

Lawrence S.L. ^{[1
]}

Roth V. ^{[2
]}

Slinger R. ^{[3
]}

Toye B. ^{[2
]}

Gaboury I. ^{[4
]}

Lemyre B. ^{[1
]}

机构：

[1] Department of Obstetrics, Gynecology and Newborn Care, The Ottawa Hospital, Ottawa, Ont. K1H 8L6

[2] Department of Microbiology, The Ottawa Hospital, Ottawa, Ont. K1H 8L6

[3] Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ont.

[4] Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ont.

来源：

BMC Pediatrics | / 5卷 / 1期

关键词：

Vancomycin; Gentamicin; Blood Culture; Neonatal Intensive Care Unit; Positive Blood Culture;

D O I：

10.1186/1471-2431-5-49

中图分类号：

学科分类号：

摘要：

Background: Coagulase negative staphylococcus (CONS) is the main cause of late-onset sepsis in Neonatal Intensive Care Units (NICU). Although CONS rarely causes fulminant sepsis, vancomycin is frequently used as empiric therapy. Indiscriminate use of vancomycin has been linked to the emergence of vancomycin resistant organisms. The objective of this study was to compare duration of CONS sepsis and mortality before and after implementation of a policy of selective vancomycin use and compare use of vancomycin between the 2 time periods. Methods: A retrospective study was conducted of infants ≥4 days old, experiencing signs of sepsis with a first positive blood culture for CONS, during two 12-month periods. Late-onset sepsis was treated empirically with vancomycin and gentamicin during period 1, and cloxacillin and gentamicin during period 2. The confidence interval method was used to assess non-inferiority of the outcomes between the two study groups. Results: There were 45 episodes of CONS sepsis during period 1 and 37 during period 2. Duration of sepsis was similar between periods (hazard ratio of 1.00, 95%CI: 0.64, 1.57). One death during period 2 was possibly related to CONS sepsis versus none in period 1. Vancomycin was used in 97.8% of episodes in period 1 versus 81.1% of episodes in period 2. Conclusion: Although we failed to show non-inferiority of duration of sepsis in the cloxacillin and gentamicin group compared to the vancomycin and gentamicin group, duration of sepsis was clinically similar. Restricting vancomycin for confirmed cases of CONS sepsis resistant to oxacillin appears effective and safe, and significantly reduces vancomycin use in the NICU. © 2005 Lawrence et al., licensee BioMed Central Ltd.

引用

页数：30

共 24 条

[1] Karlowicz M.G., Buescher E.S., Surka A.E., Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy, Pediatrics, 106, 6, pp. 1387-1390, (2000)
[2] Bonten M.J., Willems R., Weinstein R.A., Vancomycin-resistant enterococci: Why are they here, and where do they come from?, Lancet Infect. Dis., 1, 5, pp. 314-325, (2001)
[3] Martone W.J., Spread of Vancomycin-resistant, entercocci: Why did it happen in the United States?, Infect. Control Hosp. Epidemiol., 19, 8, pp. 539-545, (1998)
[4] Garrett D.O., Jochimsen E., Murfitt K., Hill B., McAllister S., Nelson P., Spera R.V., Sall R.K., Tenover F.C., Johnston J., Zimmer B., Jarvis W.R., The emergence of decreased susceptibility to vancomycin in Staphylococcus Epidermidis, Infect. Control Hosp. Epidemiol., 20, 3, pp. 167-170, (1999)
[5] Veach L.A., Pfaller M.A., Barrett M., Koontz F.P., Wenzel R.P., Vancomycin resistance in Staphylococcus Haemolyticus causing colonization and bloodstream infection, J. Clin. Microbiol., 28, 9, pp. 2064-2068, (1990)
[6] Public health dispatch: Vancomycin-resistant Staphylococcus Aureus, Morbidity and Mortality Weekly Report, 51, 40, pp. 902-904, (2002)
[7] Staphylococcus Aureus resistant to vancomycin, Morbidity and Mortality Weekly Report, 51, 26, pp. 565-567, (2002)
[8] Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin, Morbidity and Mortality Weekly Report, 46, 27, (1997)
[9] Recommendations for preventing the spread of vancomycin resistance, Infect. Control Hosp. Epidemiol., 16, pp. 105-113, (1995)
[10] Matrai-Kovalskis Y., Greenberg D., Shinwell E.S., Fraser D., Dagan R., Positive blood cultures for coagulase-negative staphylococci in neonates: Does highly selective vancomycin usage affect outcome?, Infection, 26, 2, pp. 85-92, (1998)

← 1 2 3 →